JUN 20, 2016 7:00 AM PDT

Blood test could use shapes to spot cancer

A new way to detect antibodies in blood opens the door to developing simple diagnostic tests for diseases for which no microbial cause is known, including autoimmune diseases and cancer.

The results are the first evidence that it is possible to develop blood tests for any infectious disease by screening random libraries of non-biological molecular shapes.

Image Credit: iStockPhoto

“This ‘needle-in-a-molecular haystack’ approach is a new way to develop diagnostic assays,” says senior author Donald S. Burke, dean of the Graduate School of Public Health at the University of Pittsburgh.

“The method does not rely on starting with known viral components. This is important because there are conditions for which there isn’t a known antigen, such as newly emerged epidemics, autoimmune diseases, or even responses to traumatic injury.”

When a person’s immune system is faced with an antigen or foreign invader, such as an infectious disease, or even an injury with tissue damage, it responds by producing antibodies. Like puzzle pieces, specific parts of the surface of these antibodies fit to the shape of the molecules on the invader or the damaged tissue.

As reported in the Journal of Immunological Methods, the new technique, which synthesizes random molecular shapes called “peptoids” hooked onto microscopic plastic beads, can produce millions of molecular shapes. The peptoids are not organic, but if they match to the corresponding shape on an antibody, that antibody will connect to them, allowing the scientist to pull out that bead and examine that peptoid and its corresponding antibody.

Using this technique, researchers chemically generated a huge library of random molecular shapes. Then, using blood from HIV-infected patients and from non-infected people, they screened a million of these random molecular shapes to find the ones that bound only to antibodies present in the blood of HIV-infected patients, but not the healthy controls.

No HIV proteins or structures were used to construct or select the peptoids, but the approach, nonetheless, successfully led to selection of the best molecular shapes to use in screening for HIV antibodies.

The team then resynthesized that HIV-antibody-targeting peptoid in mass and tested it by screening hundreds of samples from the Multicenter AIDS Cohort Study (MACS), a confidential research study of the natural history of treated and untreated HIV/AIDS in men who have sex with men (supported by the National Institutes of Health).

Study coauthor Charles Rinaldo, chair of the infectious diseases and microbiology department selected the samples, but blinded the testers to which samples were HIV-positive or -negative. The test distinguished between the samples of HIV-positive blood and HIV-negative blood with a high degree of accuracy.

“This technology means that we may be able to take a single drop of blood from a patient and detect antibodies to all manner of infections, cancers, or other conditions they may be carrying or been exposed to,” Burke says.

“We hope that this is the first step toward development of an ‘Epi-chip’ that can be used to reconstruct a person’s entire exposure history.”

Other researchers from University of Pittsburgh and from the University of California, San Francisco, are coauthors of the study that was funded by the Bill & Melinda Gates Foundation.

Source: University of Pittsburgh

This article was originally posted on futurity.org.
About the Author
  • Futurity features the latest discoveries by scientists at top research universities in the US, UK, Canada, Europe, Asia, and Australia. The nonprofit site, which launched in 2009, is supported solely by its university partners (listed below) in an effort to share research news directly with the public.
You May Also Like
SEP 22, 2019
Technology
SEP 22, 2019
Blood Incubation Using Laser Technology
The world’s first ever blood incubator was developed using laser technology and could someday prevent fatal blood transfusions in critically ill pati...
SEP 24, 2019
Immunology
SEP 24, 2019
Flu Shot Less Effective Due to Overuse of Antibioitics
New research out of the Stanford University School of Medicine shows that the consequence of overuse of antibiotics lowers the effectiveness of the seasona...
JAN 14, 2020
Clinical & Molecular DX
JAN 14, 2020
Can I eat this donut? A quick test for celiac disease.
Genetic testing revealed that our ancestors have been eating wheat, rye, spelt and barley for over 8,000 years. Today, gluten, a protein found within these...
FEB 24, 2020
Clinical & Molecular DX
FEB 24, 2020
Nanoparticles provide momentum for better diagnostic imaging
Photoacoustic imaging is an emerging tool with a vast array of biomedical applications ranging from the detection of brain lesions to imaging early signs o...
MAR 16, 2020
Clinical & Molecular DX
MAR 16, 2020
New diagnostic tech uses AI to screen blood for over 1400 pathogens
New and reemerging microbial threats continue to challenge the public health and infectious disease response teams worldwide. An estimated 14 million peopl...
MAR 19, 2020
Infographics
MAR 19, 2020
All You Need to Know About Coronavirus (CoVID-19)
A new coronavirus, first identified in China in December 2019, has caused an outbreak of respiratory illness that was recently named CoVID19. CoVID-19 is s...
Loading Comments...